[6] Dong Q Z, Wang Y, Dong X J, *et al*. CIP2A is overexpressed in non-small cell lung cancer and correlates with poor prognosis [J]. Ann Surg Oncol, 2011, 18(3): 857-865.
[7] Huang P, Qiu J, You J, *et al*. Expression and prognostic significance of CIP2A mRNA in hepatocellular carcinoma and nontumoral liver tissues [J/OL]. Biomarkers, 2012 [2012-04-27]. http://www.ncbi.nlm.gov/pubmed.
[8] Teng H W, Yang S H, Lin J K, *et al*. CIP2A is a predictor of poor prognosis in colon cancer [J]. J Gastrointest Surg, 2012, 16(5): 1037-1047.
[9] 钱安平, 辛彦, 肖玉平, 等. CIP2A与肿瘤关系的研究进展[J]. 世界华人消化杂志, 2009,17(26): 2700-2704.
[10] Come C, Laine A, Chanrion M, *et al*. CIP2A is associated with human breast cancer aggressivity [J]. Clin Cancer Res, 2009, 15(16): 5092-5100.
[11] Bockelman C, Koskensalo S, Hagstrom J, *et al*. CIP2A overexpression is associated with c-Myc expression in colorectal cancer [J]. Cancer Biol Ther, 2012, 13(5): 289-295.
[12] Niemela M, Kauko O, Sihto H, *et al*. CIP2A signature reveals the MYC dependency of CIP2A-regulated phenotypes and its clinical association with breast cancer subtypes [J/OL]. Oncogene, 2012 [2012-01-16]. http://www.nature.com/onc.
[13] Chen K F, Liu C Y, Lin Y C, *et al*. CIP2A mediates effects of bortezomib on phospho-Akt and apoptosis in hepatocellular carcinoma cells [J]. Oncogene, 2010, 29(47): 6257-6266.
[14] 陈应超, 何源萍, 张少容, 等. 癌基因AKT2在喉鳞状细胞癌中的表达及临床意义[J]. 临床耳鼻咽喉头颈外科杂志, 2009, 23(12): 539-541,545.
[15] Guenebeaud C, Goldschneider D, Castets M, *et al*. The dependence receptor UNC5H2/B triggers apoptosis *via* PP2A-mediated dephosphorylation of DAP kinase [J]. Mol Cell, 2010, 40(6): 863-876.
[16] Sanchez-Cespedes M, Esteller M, Wu L, *et al*. Gene promoter hypermethylation in tumors and serum of head and neck cancer patients [J]. Cancer Res, 2000, 60(4): 892-895.
[17] Dikshit R P, Gillio-Tos A, Brennan P, *et al*. Hypermethylation, risk factors, clinical characteristics, and survival in 235 patients with laryngeal and hypopharyngeal cancers [J]. Cancer, 2007, 110(8): 1745-1751.
[18] Khanna A, Okkeri J, Bilgen T, *et al*. ETS1 mediates MEK1/2-dependent overexpression of cancerous inhibitor of protein phosphatase 2A (CIP2A) in human cancer cells [J]. PLoS One, 2011, 6(3): e17979.
[19] Qu W, Li W, Wei L, *et al*. CIP2A is overexpressed in esophageal squamous cell carcinoma [J]. Med Oncol, 2012, 29(1): 113-318.
[20] Huang C Y, Wei C C, Chen K C, *et al*. Bortezomib enhances radiation-induced apoptosis in solid tumors by inhibiting CIP2A [J]. Cancer Lett, 2012, 317(1): 9-15.
[21] Tseng L M, Liu C Y, Chang K C, *et al*. CIP2A is a target of bortezomib in human triple negative breast cancer cells [J]. Breast Cancer Res, 2012, 14(2): R68.
[22] Lin Y C, Chen K C, Chen C C, *et al*. CIP2A-mediated Akt activation plays a role in bortezomib-induced apoptosis in head and neck squamous cell carcinoma cells [J]. Oral Oncol, 2012, 48(7): 585-593.

(**收稿**:2012-04-17;**修回**:2012-05-27)
(编辑 汪勤俭)

举办2012全国足踝关节镜手术理论及操作高级培训班通知

足踝疾病在临床上十分常见,关节镜手术因其创伤小、切口美观、术后功能恢复快,而受到专科医生和患者普遍好评。为了推广该项新技术,中西医结合学会重庆市骨科专委会将于2012年11月3-5日在重庆举办全国足踝关节镜手术理论及操作培训班。学习内容强调实用性和可操作性,并确保全部学员可以进行尸体操作。学员可获得国家继续教育I类学分(项目编号2012-04-07-200)。承办单位:国家卫生部关节镜培训基地-第三军医大学西南医院关节外科中心。会务组将在连续两年成功举办全国足踝手术操作培训班的基础上,再次组织专家为学员系统讲授足踝关节镜手术细节,并帮助他们开展相应临床工作。会议详情请登陆中华关节外科网(http://www.jointsurgery.com.cn)。

一、主要内容

1、常见足踝关节镜技术新进展
2、踝关节疾病的影像学诊断要点
3、踝关节、距下关节疾病诊断和关节镜手术
4、足踝肌腱镜临床应用新技术
5、足踝关节镜基本操作技术及Workshop尸体操作
6、常见踝关节镜手术演示

二、学习安排

2012年11月3日在重庆市沙坪坝区凤天路橡树林酒店(第三军医大学正门旁)大厅报到,11月4日在第三军医大学内进行理论学习和Workshop操作,11月5日参观手术。会议注册及资料费:理论学习800元、尸体操作1000元(尸体操作限报名25名学员)。食宿统一安排,住宿及交通费用自理。有意者请尽早联系并报名。

联系地址:重庆市沙坪坝区高滩岩正街29号西南医院关节外科中心,邮编400038

联系人:曾山李、段小军;电话:(023)68765293,13667680105;E-mail:jointsurgery@163.com/arthro@126.com

2012全国足踝关节镜培训班组委会